Reema Patel, MD
Medical Oncology · Lexington, KYNPI 1376801209
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,824 of the $4,511 with a category attached, or 62.6%. 14 manufacturers reported payments, led by Roche Products Limited at 50.5% of the total. Reporting peaked in 2020 at $2,506 and has fallen 93.1% since, to $173 in 2025. That places this record below the midpoint for medical oncology clinicians in KY, where the typical reported total is $3,396.
Across 32 payments — averaging $140.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Roche Products Limited$2K
- Ipsen Biopharmaceuticals, Inc$412
- Tempus AI, Inc$345
- Exelixis Inc.$271
- AstraZeneca$256
- Abbott$179
- plus $772 from 8 others
Across 100 payments — averaging $6512.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Exelixis Inc.$203K
- AstraZeneca$140K
- Genentech, Inc.$109K
- GSK$98K
- Ipsen Bioscience Inc.$93K
- Merck$4K
- plus $4K from 1 others
What the payments were for
- Travel & lodging$1,68737%
- Food & beverage$2,82463%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Roche Products Limited | 3 | $2,276 |
| Ipsen Biopharmaceuticals, Inc | 5 | $412 |
| Tempus AI, Inc | 3 | $345 |
| Exelixis Inc. | 2 | $271 |
| AstraZeneca | 3 | $256 |
| Abbott | 8 | $179 |
| Sirtex Medical Inc | 1 | $153 |
| Genentech, Inc. | 1 | $137 |
| Genentech USA, Inc. | 1 | $136 |
| Intera Oncology, Inc | 1 | $123 |
| Vertex | 1 | $102 |
| Epizyme, Inc. | 1 | $86 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Beigene USA, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Avastin$2,549
- TECENTRIQ$2,413
- XT CDX$222
- Cabometyx$162
- SIR-Spheres Microspheres$153
- IMFINZI$124
- INTERA$123
- SOMATULINE DEPOT$117
- ONIVYDE$117
How this compares
$4,511 in reported general payments places this provider in the 50th percentile of 53 medical oncology providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| CabometyxCabozantinib S-Malate | 19 | $490,319 |
| QinlockRipretinib | 13 | $477,138 |
| LonsurfTrifluridine/Tipiracil Hcl | 14 | $223,775 |
| Imatinib Mesylate | 183 | $215,204 |
| ErleadaApalutamide | 13 | $174,582 |
| IbrancePalbociclib | 11 | $163,777 |
| MekinistTrametinib Dimethyl Sulfoxide | 12 | $161,884 |
| TafinlarDabrafenib Mesylate | 12 | $149,104 |
| Sunitinib Malate | 17 | $138,573 |
| XtandiEnzalutamide | 14 | $135,417 |
| CreonLipase/Protease/Amylase | 34 | $123,840 |
| SorafenibSorafenib Tosylate | 25 | $87,918 |
| OrgovyxRelugolix | 23 | $58,569 |
| EliquisApixaban | 46 | $35,367 |
| Sirolimus | 16 | $31,909 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Exelixis Inc.Cabometyx | $271 | $490,31919 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 53 medical oncology providers in Kentucky.
Other medical oncology in Lexington
- Lowell AnthonyLexington$55K
- Zhonglin HaoLexington$15K
- Arvinda PadmanabhanLexington$13K
- Shawn PetersonLexington$11K
- Peng WangLexington$8K
- Zin MyintLexington$7K
- Natalie HarperLexington$6K
- Ralph ZinnerLexington$5K
- Janeesh Sekkath-VeeduLexington$1K
- Mohamed AlsharediLexington$594
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.